LungLife AI, INC Director/PDMR Shareholding (5436E)

TIDMLLAI

RNS Number : 5436E

LungLife AI, INC

08 July 2021

LungLife AI, Inc.

("LungLife" or the "Company")

Director/PDMR Notification

LungLife (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US $0.0001 each ("Common Shares") undertaken by directors.

The transactions were made in connection with the placing of new Common Shares in the capital of the Company as part of the Company's admission to trading on AIM.

Roy Davis, Non-Executive Chair, has today purchased 14,204 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Davis now holds 14,204 Common Shares, representing approximately 0.06% of the outstanding share capital of the Company.

In addition, Andrew Boteler, Non-Executive Director, has today purchased 5,681 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Boteler now holds 5,681 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        1) Roy Davis 
                                   2) Andrew Boteler 
     ---------------------  --------------------------------------------- 
 2    Reason for the notification 
     -------------------------------------------------------------------- 
 a)   Position/status             1) Non-Executive Chairman 
                                   2) Non-Executive Director 
     ---------------------  --------------------------------------------- 
 b)   Initial notification        1) Initial notification 
       /Amendment                  2) Initial notification 
     ---------------------  --------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------- 
 a)   Name                   LungLife AI, Inc. 
     ---------------------  --------------------------------------------- 
 b)   LEI                     549300VBVDIF0Y3OVI38 
     ---------------------  --------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     -------------------------------------------------------------------- 
 a)   Description            Common shares of $0.0001 each in the capital 
       of the financial       of the Company 
       instrument, 
       type of instrument     ISIN: USU5500L1045 
       Identification 
       code 
     ---------------------  --------------------------------------------- 
 b)   Nature of the          Purchase of Common Shares 
       transaction 
     ---------------------  --------------------------------------------- 
 c)   Price(s) and            Price        No. of shares 
       volume(s)               1) 176.0p    1) 14,204 
                                2) 176.0p    2) 5,681 
                                           -------------- 
     ---------------------  --------------------------------------------- 
 d)   Aggregated              N/a - single transaction 
       information 
       - Aggregated 
       volume 
       - Price 
     ---------------------  --------------------------------------------- 
 e)   Date of the            8 July 2021 
       transaction 
     ---------------------  --------------------------------------------- 
 f)   Place of the           London Stock Exchange, AIM 
       transaction 
     ---------------------  ---------------------------------------------

- Ends -

For further information please contact:

 
LungLife AI, Inc.                                                      www.lunglifeai.com 
Paul Pagano, CEO                                                          Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                             Tel: +44 (0)20 7597 5970 
 & Broker) 
Daniel Adams / Virginia Bull / Cameron 
 MacRitchie 
 
Walbrook PR Limited                 Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings                              Mob: 07980 541 893 / 07407 804 
                                                                                      654

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDKOBNBBKBNOK

(END) Dow Jones Newswires

July 08, 2021 03:00 ET (07:00 GMT)

Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024